Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Laninamivir's prolonged intrapulmonary retention: Intrapulmonary pharmacokinetics (PK) and the intracellular disposition to support the long-lasting efficacy after an inhaled administration of its prodrug laninamivir octanoate (LO)

Hidetoshi Furuie, Kaoru Toyama, Kumiko Koyama, Daisuke Nakai, Hitoshi Ishizuka
European Respiratory Journal 2013 42: P727; DOI:
Hidetoshi Furuie
1OPHAC Hosptal, Heishinkai Medical Group Incorporated, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaoru Toyama
2Translational Medicine and Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kumiko Koyama
2Translational Medicine and Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daisuke Nakai
2Translational Medicine and Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hitoshi Ishizuka
2Translational Medicine and Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 42 no. Suppl 57

Published By 
European Respiratory Society
Print ISSN 
0903-1936
Online ISSN 
1399-3003
History 
  • Published online July 25, 2014.

Copyright & Usage 
© 2013 ERS

Author Information

  1. Hidetoshi Furuie1,
  2. Kaoru Toyama2,
  3. Kumiko Koyama2,
  4. Daisuke Nakai2 and
  5. Hitoshi Ishizuka2
  1. 1OPHAC Hosptal, Heishinkai Medical Group Incorporated, Osaka, Japan
  2. 2Translational Medicine and Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan

Article usage

Article usage: August 2014 to February 2023

AbstractFullPdf
Aug 2014200
Sep 2014202
Oct 2014602
Nov 2014302
Jan 2015703
Feb 2015100
Mar 2015401
May 2015001
Jul 2015100
Aug 2015001
Sep 2015200
Oct 2015200
Dec 2015400
Jan 2016401
Feb 2016202
Mar 2016300
May 2016202
Jun 2016602
Jul 2016800
Aug 2016302
Sep 2016902
Oct 2016304
Nov 2016403
Dec 2016301
Jan 2017400
Feb 2017600
Mar 20172012
Apr 2017100
May 2017209
Jun 2017100
Jul 2017107
Aug 2017301
Sep 2017801
Oct 2017102
Nov 2017400
Dec 2017100
Jan 2018600
Feb 2018303
Mar 2018503
Apr 2018401
May 2018205
Jun 2018203
Jul 20181000
Sep 2018201
Oct 2018100
Nov 2018500
Dec 2018102
Jan 2019600
Apr 2019301
May 2019300
Jun 2019002
Jul 2019502
Aug 2019701
Sep 2019701
Oct 2019300
Nov 2019100
Dec 20191603
Jan 2020202
Mar 20201000
Apr 2020501
May 2020001
Jun 20201000
Jul 20201000
Aug 2020100
Sep 20201101
Oct 2020300
Nov 20203304
Dec 2020101
Jan 20211102
Feb 2021101
Mar 20214100
Apr 2021501
May 2021400
Jun 2021302
Jul 2021403
Aug 20212804
Sep 2021400
Oct 2021401
Nov 20211807
Dec 20212601
Jan 20222600
Feb 2022700
Mar 2022401
Apr 20221306
May 20221502
Jun 20222300
Jul 20222007
Aug 20222203
Sep 2022102
Oct 2022100
Nov 2022600
Dec 20221705
Jan 2023100
Feb 2023001

Altmetrics

Previous
Back to top
Vol 42 Issue Suppl 57 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Laninamivir's prolonged intrapulmonary retention: Intrapulmonary pharmacokinetics (PK) and the intracellular disposition to support the long-lasting efficacy after an inhaled administration of its prodrug laninamivir octanoate (LO)
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Laninamivir's prolonged intrapulmonary retention: Intrapulmonary pharmacokinetics (PK) and the intracellular disposition to support the long-lasting efficacy after an inhaled administration of its prodrug laninamivir octanoate (LO)
Hidetoshi Furuie, Kaoru Toyama, Kumiko Koyama, Daisuke Nakai, Hitoshi Ishizuka
European Respiratory Journal Sep 2013, 42 (Suppl 57) P727;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Laninamivir's prolonged intrapulmonary retention: Intrapulmonary pharmacokinetics (PK) and the intracellular disposition to support the long-lasting efficacy after an inhaled administration of its prodrug laninamivir octanoate (LO)
Hidetoshi Furuie, Kaoru Toyama, Kumiko Koyama, Daisuke Nakai, Hitoshi Ishizuka
European Respiratory Journal Sep 2013, 42 (Suppl 57) P727;
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Maintenance of IRF1 by MAPK inhibition: A mechanism by which DUSP1 reduces glucocorticoid inhibition of CXCL10
  • Omalizumab, airway obstruction and remodeling
  • Central role for the TRPV4-ATP-P2X3 axis in sensory nerve activation and the late asthmatic response
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society